Data compiled by Redley Lamar · ChainSifter Intelligence
10Suppliers
9Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Celldex Therapeutics, Inc. (CLDX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
21Total relationships
3Distinct source URLs
6High confidence
0.770Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Celldex Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CDMOS
CDMOS
92%
We rely on CDMOs over whom we have limited control. Should the cost, delivery and quality of clinical materials manufactured by us in our Fall River facility or supplied by CDMOs vary to our disadvan…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
92%
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representa…
TD-SECURITIES-USA-LLC
TD-SECURITIES-USA-LLC
92%
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representa…
Reciprocal relationship from IBIO graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for ma…
Reciprocal relationship from JSPR graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from JSPR graph: h third parties to market and sell our product candidates, if approved, we m…
Reciprocal relationship from JSPRW graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from JSPRW graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from JSPR…
Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitab…
Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS g…
Reciprocal relationship from SEPN graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties …
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from SNYN…
Celldex Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
ROCKEFELLER-UNIVERSITY
ROCKEFELLER-UNIVERSITY
90%
The Company recognized $ 0.0 million and $ 0.6 million in revenue under the agreements with Rockefeller during the three months ended March 31, 2026, and 2025, respectively.
Reciprocal relationship from IBIO graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO g…
Reciprocal relationship from JSPR graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from JSPR graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from JSPR g…
Reciprocal relationship from JSPRW graph: with third parties to market and sell our product candidates, if approved, we may not be able to effectively market and sell our product candidates, if appro…
Reciprocal relationship from PYXS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS g…
Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufa…
SNYNF
Sanofi
72%
gs; ● restrictions on operations, including costly new manufacturing requirements; or ● seizure or detention of drugs or import bans. The regulatory requirements and policies may change and additiona…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX graph: gs; ● restrictions on operations, including costly new manufacturing requirements; or ● seizure or detention of drug…
KOLLTAN-PHARMACEUTICALS-INC
KOLLTAN-PHARMACEUTICALS-INC
62%
ce obligations in the contract; and ● Recognition of revenue when, or as, the Company satisfies a performance obligation. Revenue for the Company is derived from product development agreements with c…
Celldex Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CLDX-DEBT
Debt stack $1.9M
90%
Market cache reports total debt of $1.9M.
Celldex Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Celldex Therapeutics, Inc..
Celldex Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CLDX-OWNER-WELLINGTON-MANAGEMENT-GROUP-LLP
WELLINGTON MANAGEMENT GROUP LLP
90%
13F overlay lists WELLINGTON MANAGEMENT GROUP LLP as top holder; 232 tracked holders.
Celldex Therapeutics, Inc. Extended Supply Chain Network
